NEW YORK (AP) -- Drug developer Genta Inc. said Wednesday a Food and Drug Administration advisory committee recommended against approving the company's leukemia treatment candidate. The panel's recommendation is part of an ongoing review by the FDA for the drug candidate Genasense, an injectable drug aimed at treating a form of blood cancer called refractory chronic lymphocytic leukemia, in conjunction with chemotherapy. The FDA is expected to decide on whether to approve the drug by Oct. 29 and usually follows the recommendations of its advisory committees.
This drug is most likely dead in the water. Ouch.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment